J&J Growth Plans Heavy On Line Extensions, Sticking With Immunology And Oncology
Executive Summary
Recent launches Tremfya and Erleada are viewed as catalysts for continuing growth, along with ambitious plans to add indications for Imbruvica, Darzalex and Stelara.
You may also be interested in...
ECLIPSE: J&J's Tremfya Beats Novartis' Cosentyx For Long-Term Psoriasis Clearance
Novartis stresses long-term safety database for Cosentyx – with five years' worth of data in three indications – psoriasis, psoriatic arthritis and ankylosing spondylitis.
Yuhan Strikes Long-Awaited Lung Cancer Deal Through Huge Janssen Alliance
Yuhan inks long-awaited, major global license agreement for its novel third-generation EGFR TKI with Janssen, in a $1.2bn deal poised to boost the South Korean firm's ongoing R&D efforts in key therapeutic areas, while Janssen will further beef up its oncology portfolio. But competition with entrenched rival Tagrisso awaits.
CLL Sector Heats Up, AbbVie/Roche Upbeat About First-Line Venetoclax Combo
Positive top-line data on use of an AbbVie/Genentech's venetoclax combination as a first-line chronic lymphocytic leukemia therapy heralds stiffer competition in the therapeutic sector in the years to come.